

5 August 2008

Market Update

Antisense Therapeutics Limited (ASX:ANP) wishes to provide information on its developmental compound for multiple sclerosis (MS), ATL/TV1102. This information is provided in response to recent news regarding a currently-marketed 3rd party MS product that influences the immune system protein VLA-4 (Very Late Antigen-4).

ANP's product ATL/TV1102 is a second-generation antisense inhibitor of CD49d, a subunit of VLA-4, a clinically validated target in the treatment of MS. ATL/TV1102 works by binding to the mRNA of VLA-4. Importantly, ATL/TV1102 has a different mechanism of action, site of action and pharmacokinetic (PK) distribution profile than any currently-marketed MS treatments.

There are no indications suggesting that ATL/TV1102 may be associated with a risk of progressive multifocal leukoencephalopathy (PML), and our clinical trials on ATL/TV1102 have shown no evidence of JC virus activation or PML. The development of ATL/TV1102 continues, following the recent completion of a Phase IIa study of the product that involved 77 patients on product for eight weeks.

Further information on ATL/TV1102 can be found at www.antisense.com.au.

About ATL/TV1102 for MS

ATL/TV1102 is a second-generation antisense drug discovered by Isis Pharmaceuticals Inc. and licensed to ANP. Antisense drugs block specifically disease-causing proteins from being produced by interacting with their intended target based on information in the genetic code. ATL/TV1102 is a second-generation antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). In inflammation, white blood cells (leukocytes) move out of the bloodstream into the inflamed tissue, for example, the CNS in MS, and the lung airways in asthma. The inhibition of VLA-4 may prevent white blood cells from entering sites of inflammation, thereby halting progression of the disease. VLA-4 is a clinically validated target in the treatment of MS. Antisense inhibition of VLA-4 has demonstrated positive effects in a number of animal models of inflammatory disease including MS (Myers et al. J Neuroimmunol 160, p12-24, 2005).

About Antisense Therapeutics Limited

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialize antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL/TV1102 (injection) has completed a Phase IIa trial as a potential treatment of multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering pre-clinical development as a potential treatment for acromegaly and vision disorders. ATL/TV1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical research stage being investigated as a potential treatment for prostate cancer. ATL/TV1102 has been licensed to Teva Pharmaceutical Industries Ltd.

Contact Information:

Website: www.antisense.com.au
Managing Director – Mark Diamond +61 3 9827 8999
Investor Relations – Simon Watkin +61 (0) 413 153272